Source-grounded facts extracted from MADRIGAL PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
John C. Reed was elected as Director at MADRIGAL PHARMACEUTICALS, INC..
“On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.”
MADRIGAL PHARMACEUTICALS, INC. shareholders approved Approval of 2026 ESPP at the 2026-06-17 meeting.
“5. The Company’s stockholders approved the 2026 ESPP. The voting results were as follows: For Against Abstentions Broker Non-Votes 19,546,766 22,948 21,270 1,731,844”
MADRIGAL PHARMACEUTICALS, INC. shareholders approved Approval of 2026 Stock Plan at the 2026-06-17 meeting.
“4. The Company’s stockholders approved the 2026 Stock Plan. The voting results were as follows: For Against Abstentions Broker Non-Votes 19,118,851 446,394 25,739 1,731,844”
MADRIGAL PHARMACEUTICALS, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor at the 2026-06-17 meeting.
“3. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: For Against Abstentions 21,256,315 37,505 29,009”
MADRIGAL PHARMACEUTICALS, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-17 meeting.
“2. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows: For Against Abstentions Broker Non-Votes 19,000,895 561,058 29,031 1,731,844”
MADRIGAL PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2026-06-17 meeting.
“1. The Company’s stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders or until his successor is duly elected and qualified. The voting results were as follows: For Withheld Broker Non-Votes Julian C. Baker 17,363,250 2,227,734 1,731,844 Daniel J. Brennan 19,469,200 121,784 1,731,844 James M. Daly 18,921,185 669,799 1,731,844”
MADRIGAL PHARMACEUTICALS, INC. reported the quarter ended March 31, 2026 results: revenue $311.3 million, net income ($94.4 million) or ($3.25) per share (basic and diluted), EPS ($3.25).
“(EX-99.1) --- Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates • First-quarter 2026 Rezdiffra ® (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and”
MADRIGAL PHARMACEUTICALS, INC. amended First Amendment to the Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) (effective 2026-01-29).
“On January 29, 2026 (the “Effective Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment (the “Amendment”) to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche.”
Rebecca Taub changed role as Senior Scientific and Medical Advisor at MADRIGAL PHARMACEUTICALS, INC..
“Pursuant to the Letter Agreement, effective as of April 21, 2025, Dr. Taub will transition from her current role and responsibilities to a new role as a Senior Scientific and Medical Advisor to the Company through the end of 2025.”
Jackie Fouse was elected as Director at MADRIGAL PHARMACEUTICALS, INC..
“On March 10, 2025, following the recommendation of its Nominating and Governance Committee, the Board expanded the size of the Board from nine to ten members and elected Jackie Fouse, Ph.D. to fill the newly created vacancy.”
Fred Craves resigned as Director at MADRIGAL PHARMACEUTICALS, INC..
“On March 9, 2025, Fred Craves, Ph.D. provided notice of his resignation from the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), effective as of July 1, 2025.”
MADRIGAL PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC (effective 2024-05-07).
“The Sales Agreement replaces and supersedes the prior sales agreement, dated June 1, 2021 and amended on May 9, 2023, between the Company and Cowen and Company, LLC, an affiliate of TD Cowen (the “Prior Sales Agreement”), which was terminated effective upon the entry into the Sales Agreement.”
MADRIGAL PHARMACEUTICALS, INC. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $300,000,000 (effective 2024-05-07).
“On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC, (“TD Cowen”), pursuant to which the Company may issue and sell through or to TD Cowen, acting as agent or principal, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time having an aggregate sales price of up to $300,000,000 (the “ATM Offering”).”
MADRIGAL PHARMACEUTICALS, INC. reported financial results for first-quarter 2024.
“On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2024.”
MADRIGAL PHARMACEUTICALS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co valued at approximately $574.0 million (effective 2024-03-18).
“On March 18, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co, as representatives of the several underwriters named therein (the “Underwriters”), for the sale of (i) 750,000 shares of common stock (the “Shares”) of the Company, $0.0001 par value per share (the “Common Stock”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,557,692 shares of Common Stock in an underwritten public offering (the “Offering”).”
Mardi C. Dier was appointed as Senior Vice President and Chief Financial Officer at MADRIGAL PHARMACEUTICALS, INC..
“On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mardi C. Dier as Senior Vice President and Chief Financial Officer of the Company, effective March 11, 2024.”
MADRIGAL PHARMACEUTICALS, INC. reported financial results for third quarter 2023.
“On November 6, 2023, Madrigal Pharmaceuticals, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2023.”
MADRIGAL PHARMACEUTICALS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein valued at approximately $472.0 million (effective 2023-09-28).
“Madrigal Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein”
Remy Sukhija resigned as Chief Commercial Officer at MADRIGAL PHARMACEUTICALS, INC..
“Madrigal Pharmaceuticals, Inc. (the “Company”) reports that Remy Sukhija, who has served as the Company’s Chief Commercial Officer since April of 2020, is leaving the Company to pursue other opportunities.”
Paul Friedman departed as Chief Executive Officer at MADRIGAL PHARMACEUTICALS, INC..
“As of the Start Date, Dr. Friedman stepped down as Chief Executive Officer but will continue to serve as a director of the Company.”
Bill Sibold was appointed as President and Chief Executive Officer at MADRIGAL PHARMACEUTICALS, INC..
“The Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) appointed Bill Sibold as the President and Chief Executive Officer of the Company, increased the Board size to nine and appointed Bill Sibold as a member of the Board, in each case effective as of 5:01 p.m. ET on September 8, 2023 (the “Start Date”).”
Raymond Cheong was appointed as Class III Director at MADRIGAL PHARMACEUTICALS, INC..
“On June 15, 2023, Julian Baker and Raymond Cheong were appointed to the Board as Class III directors, effective immediately.”
Julian Baker was appointed as Director and Chairman at MADRIGAL PHARMACEUTICALS, INC..
“Julian Baker was appointed to serve as the independent Chairman of the Board of Directors.”
David Milligan resigned as Class III Director at MADRIGAL PHARMACEUTICALS, INC..
“On June 15, 2023, Keith R. Gollust and David Milligan, Ph.D., each Class III directors on the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), resigned from the Board, effective immediately.”
Keith R. Gollust resigned as Class III Director at MADRIGAL PHARMACEUTICALS, INC..
“On June 15, 2023, Keith R. Gollust and David Milligan, Ph.D., each Class III directors on the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), resigned from the Board, effective immediately.”
MADRIGAL PHARMACEUTICALS, INC. reported financial results for first quarter 2023.
“On May 9, 2023, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2023.”
MADRIGAL PHARMACEUTICALS, INC. amended term loan of aggregate of $250.0 million in term loans; Tranche 2 increased by $15.0 million to $65.0 million; Tranche 4 reduced by $ with Hercules Capital, Inc. at variable per annum rate determined based on the greater of (i) the prime rate as maturing May 1, 2026, extendable for one year upon Approval Milestone.
“nt, dated May 9, 2022 (the “Loan Agreement” and as amended by the Amendment, the “Amended Loan Agreement”), with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”), and Hercules Capital, Inc., a Maryland corporation (“Hercules”), as Lender and in its capacity as administrative agent and collateral agent for the Lenders (in such capacity, “Agent”).”
MADRIGAL PHARMACEUTICALS, INC. amended First Amendment to the Loan and Security Agreement with Hercules Capital, Inc., as Lender and Agent valued at $250.0 million (effective 2023-02-03).
“entered into a First Amendment (the “Amendment”) to the Loan and Security Agreement, dated May 9, 2022 (the “Loan Agreement””
MADRIGAL PHARMACEUTICALS, INC.: Filed a Certificate of Designation to establish the terms of a new Series B Convertible Preferred Stock (effective 2022-12-22).
“On December 22, 2022, in connection with the Offering, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware.”
MADRIGAL PHARMACEUTICALS, INC. amended Amendment with funds affiliated with Baker Bros. Advisors LP (the “Baker Bros. Investors”) (effective 2022-12-22).
“On December 22, 2022, the Company also entered into an amendment (the “Amendment”) to that certain Securities Purchase Agreement, dated June 20, 2017, with funds affiliated with Baker Bros. Advisors LP (the “Baker Bros. Investors”).”
MADRIGAL PHARMACEUTICALS, INC. entered into Securities Purchase Agreement with a group of institutional investors (collectively, the “ Investors ”) valued at $100 million (effective 2022-12-21).
“On December 21, 2022, Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with a group of institutional investors (collectively, the “ Investors ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.